Literature DB >> 14599475

Functionality of cultured human hepatocytes from elective samples, cadaveric grafts and hepatectomies.

A Serralta1, M T Donato, F Orbis, J V Castell, J Mir, M J Gómez-Lechón.   

Abstract

The major possible sources of human liver for hepatocyte isolation are elective liver biopsies, cadaveric liver grafts and therapeutic liver resections. The suitability in terms of metabolic-competent hepatocyte cultures and risk/benefit of these resources has been comparatively studied. To this end, viability of isolated hepatocytes, yield of isolation procedure, hepatocyte survival during culture and CYP activities were the parameters analysed. The best results were found in hepatocytes prepared from elective biopsies, whereas a marked reduction in viability and functional competence was seen in hepatocytes from hepatectomy samples. Metabolic differences were observed in total CYP oxidative metabolism (7-ethoxycoumarin O-deethylation, total testosterone hydroxylation), as well as in CYP3A4, CYP2C9 or CYP2C19 activities (testosterone oxidations at 6beta-, 16beta- and 17-positions, respectively). Vascular control during the hepatectomy procedure influenced hepatocyte functionality: higher CYP activities were found in hepatocytes isolated from samples obtained under non-ischemic conditions or continuous vascular clamping than in those obtained under intermittent vascular clamping. In addition to cellular functionality, other criteria such as sample availability or ethical aspects should be considered. Elective biopsies have low, but not absent, surgical risk. However, the better functionality and the higher accessibility of elective liver samples in comparison to the other groups suggest this source of liver tissue as the most appropriate for cell harvesting purposes.

Entities:  

Mesh:

Year:  2003        PMID: 14599475     DOI: 10.1016/s0887-2333(03)00122-x

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

Review 1.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Bone marrow stem cells and liver regeneration.

Authors:  Graça Almeida-Porada; Esmail D Zanjani; Christopher D Porada
Journal:  Exp Hematol       Date:  2010-04-24       Impact factor: 3.084

Review 3.  Hepatocyte transplantation program: Lessons learned and future strategies.

Authors:  Eugenia Pareja Ibars; Miriam Cortes; Laia Tolosa; Maria José Gómez-Lechón; Slivia López; José Vicente Castell; José Mir
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

4.  Clinical Hepatocyte Transplantation: What Is Next?

Authors:  James E Squires; Kyle A Soltys; Patrick McKiernan; Robert H Squires; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Curr Transplant Rep       Date:  2017-10-14

5.  An algorithm that predicts the viability and the yield of human hepatocytes isolated from remnant liver pieces obtained from liver resections.

Authors:  Serene M L Lee; Celine Schelcher; Rüdiger P Laubender; Natalja Fröse; Reinhard M K Thasler; Tobias S Schiergens; Ulrich Mansmann; Wolfgang E Thasler
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

6.  Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability.

Authors:  Samantha J Richardson; April Bai; Ashutosh A Kulkarni; Mehran F Moghaddam
Journal:  Drug Metab Lett       Date:  2016

7.  In Vitro Liver Metabolism of Six Flavonoid C-Glycosides.

Authors:  Martina Tremmel; Christian Paetz; Jörg Heilmann
Journal:  Molecules       Date:  2021-11-01       Impact factor: 4.411

8.  Hepatocyte isolation from resected benign tissues: Results of a 5-year experience.

Authors:  Fan-Ying Meng; Li Liu; Jun Liu; Chun-You Li; Jian-Ping Wang; Feng-Hui Yang; Zhi-Shui Chen; Ping Zhou
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.